

## Supplemental Material

### Profiling Environmental Chemicals for Activity in the Antioxidant Response Element Signaling Pathway Using a High-Throughput Screening Approach

Sunita J. Shukla, Ruili Huang, Steven O. Simmons, Raymond R. Tice, Kristine L. Witt, Danielle VanLeer, Ram Ramabhadran, Christopher P. Austin, and Menghang Xia

#### Table of Contents

<i>Cell Culture and Conditions</i>	2
<i>Control well layout for the primary screening</i>	2
<i>Chemical Analysis for Compound Purity</i>	3
<i>References</i>	16

#### Tables

Table S1. Activities and potencies for compounds from primary qHTS screen	4
Table S2. Activities and potencies for compounds from primary qHTS screen	5
Table S3. Activities and potencies for 34 compounds overlapping ARE- <i>bla</i> and ARE- <i>luc</i> assays in the primary qHTS screen	6
Table S4. Potencies ( $\mu$ M) and efficacies (%) of compounds from ARE confirmation studies	7

#### Figures

Figure S1. Heat map of all follow-up compounds tested in ARE- <i>bla</i> , ARE- <i>bla</i> -mut, and ARE- <i>luc</i> assays.	14
Figure S2. A flowchart of identification of ARE inducers in multiple assay formats using qHTS	15

## Cell Culture and Conditions

For the ARE-*bla*-mut assay, a stable  $\beta$ -lactamase reporter cell line utilizing the ARE mutant enhancer/promoter element derived from the ARE mutant reporter construct was constructed as follows: The  $\beta$ -lactamase open reading frame from pcDNA6.2-cGeneBlazer (Invitrogen) was isolated by PCR using the following primers:

for 5-GAATCACTCGAGATGGACCCAGAAACGCTGGT-3'

rev 5'-GAATCATCTAGATTACCAATGCTTAATCAGTGAGGCAC-3'

The resulting PCR product was subcloned into pTRED-ARE mut/*luc* (Simmons et al. 2011) between the XhoI and XbaI restriction sites, replacing the luciferase open reading frame and resulting in an ARE mutant-driven  $\beta$ -lactamase reporter that was confirmed by fluorescent DNA capillary sequencing. A lentiviral vector for ARE-*bla*-mut was generated and titered as previously described (Simmons et al. 2011). HepG2 cells were transduced with ARE-*bla*-mut lentiviral vector at a multiplicity of infection of 10. Cells were allowed to grow in culture for seven days post-transduction to amplify cell number. All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% dialyzed fetal bovine serum, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 50 U/mL penicillin and 50  $\mu$ g/mL streptomycin at 37°C in a humidified 5% CO<sub>2</sub> incubator. All tissue culture reagents were purchased from Invitrogen.

## Control well layout for the primary screening

Control wells were arrayed as follows: arrayed as follows: Column 1, concentration response titration of  $\beta$ -naphthoflavone from 46  $\mu$ M to 1.4 nM; Column 2, 23  $\mu$ M  $\beta$ -naphthoflavone; Column 3, DMSO only; Column 4, 46  $\mu$ M  $\beta$ -naphthoflavone. Columns 1 and 3 were identical between the ARE-*bla* and ARE-*luc* primary screening,

while columns 2 and 4 contained 12  $\mu$ M  $\beta$ -naphthoflavone and 6  $\mu$ M  $\beta$ -naphthoflavone, respectively, in the ARE-*luc* assay.

### **Chemical Analysis for Compound Purity**

Analytical analysis of the compounds was performed on a Waters Acquity LC/MS (Waters Corporation, Milford, MA, USA). A 2.2 minute gradient of 5 to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used at a flow rate of 0.5 mL/min. A Phenomenex Luna C18, 2.0 x 100 mm, column with a 2.5  $\mu$ m particle size was used at a temperature of 45°C. Purity determination was performed using an Evaporative Light Scattering Detector and a Photo Diode Array Detector. Mass Determination was performed using a Waters Micromass ZQ mass spectrometer with electrospray. Data was analyzed using the Waters OpenLynx software. Samples failed to pass QC due to impurities present in the sample or the inability to confirm the molecular weight of the compound with the available resources.

Supplemental Material, Table S1: Activities and potencies for compounds from primary qHTS screen

EC <sub>50</sub> (μM)	ARE- <i>bla</i> Curve Classification				
	1.1	1.2	2.1	2.2	Total (%)
<1	3	1	0	0	4 (0.3)
>1 to 10	24	6	6	5	41 (3.1)
>10 to 100	18	7	209	109	343 (25.6)
Total per classification	45	14	215	114	388 (28.9)
% Library*	3.3	1.0	16.0	8.5	28.9

\*Based on 1,340 unique compounds

EC<sub>50</sub> (concentration of half the maximal activity) and efficacy (activation as % positive control) were calculated from the concentration response curves of each individual compound. The four major curve classes (1-4) were defined by previously published criteria (Inglese et al., 2006; Huang et al., 2011; Xia et al., 2008). Briefly, curve classes 1.1, 1.2, 2.1, and 2.2 provide the highest confidence data (and are associated with active compounds), while all non-curve class 4 curves provide lower confidence data (and are associated with inconclusively active compounds). Curve class 4 compounds do not show any concentration response data and are deemed inactive.

Supplemental Material, Table S2: Activities and potencies for compounds from primary qHTS screen

EC <sub>50</sub> (μM)	ARE- <i>luc</i> Curve Classification				
	1.1	1.2	2.1	2.2	Total (%)
<1	0	0	2	0	2 (0.2)
>1 to 10	2	1	1	0	4 (0.3)
>10 to 100	1	2	19	16	38 (2.8)
Total per classification	3	3	22	16	44 (3.3)
% Library*	0.2	0.2	1.6	1.2	3.3

\*Based on 1,340 unique compounds

EC<sub>50</sub> (concentration of half the maximal activity) and efficacy (activation as % positive control) were calculated from the concentration response curves of each individual compound. The four major curve classes (1-4) were defined by previously published criteria (Inglese et al., 2006; Huang et al., 2011; Xia et al., 2008). Briefly, curve classes 1.1, 1.2, 2.1, and 2.2 provide the highest confidence data (and are associated with active compounds), while all non-curve class 4 curves provide lower confidence data (and are associated with inconclusively active compounds). Curve class 4 compounds do not show any concentration response data and are deemed inactive.

Supplemental Material, Table S3: Activities and potencies for 34 compounds overlapping ARE-*bla* and ARE-*luc* assays in the primary qHTS screen









EC <sub>50</sub> (μM)	ARE- <i>bla</i> (ARE- <i>luc</i> Curve Classification)*				
	1.1	1.2	2.1	2.2	Total
<1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
>1 to 10	7 (2)	0 (1)	1 (1)	0 (0)	8 (4)
>10 to 100	5 (1)	0 (2)	19 (17)	2 (10)	26 (30)
Total per classification	12 (3)	0 (3)	20 (18)	2 (10)	34 (34)
% Library**	0.9 (0.2)	0 (0.2)	1.5 (1.3)	0.1 (0.7)	2.5 (2.5)











\*Numbers in parentheses denote those associated with ARE-*luc* assay

\*\*Based on 1,340 unique compounds










EC<sub>50</sub> (concentration of half the maximal activity) and efficacy (activation as % positive control) were calculated from the concentration response curves of each individual compound. The four major curve classes (1-4) were defined by previously published criteria (Inglese et al., 2006; Huang et al., 2011; Xia et al., 2008). Briefly, curve classes 1.1, 1.2, 2.1, and 2.2 provide the highest confidence data (and are associated with active compounds), while all non-curve class 4 curves provide lower confidence data (and are associated with inconclusively active compounds). Curve class 4 compounds do not show any concentration response data and are deemed inactive.








Supplemental Material, Table S4: Potencies ( $\mu\text{M}$ ) and efficacies (%) of compounds from ARE confirmation studies









Compound	Structure	Cluster	ARE- <i>bla</i> EC <sub>50</sub> , $\mu\text{M}$ (Efficacy, %)	ARE- <i>bla</i> mutant IC <sub>50</sub> , $\mu\text{M}$ (Efficacy, %)	ARE- <i>luc</i> EC <sub>50</sub> , $\mu\text{M}$ (Efficacy, %)
1,10-Phenanthroline monohydrate		1	inactive	inactive	inactive
1,3-Dinitronaphthalene		2	1.2 $\pm$ 0.2 (80)	inactive	16.2 $\pm$ 11 (180)
2,3,4,5-Tetrachloronitrobenzene		3	9.4 $\pm$ 3.2 (56)	inactive	27.7 $\pm$ 6.7 (124)
2-Amino-4-chlorophenol		4	7.0 $\pm$ 1.8 (72)	inactive	6.3 $\pm$ 2.1 (175)
2-Amino-4-methylbenzothiazole		5	10.1 $\pm$ 2.1 (49)	inactive	inactive
2-Amino-4-methylphenol		6	12.0 $\pm$ 4.8 (76)	inactive	24.0 $\pm$ 7.1 (90)
2-Amino-6-nitrobenzothiazole		5	16.7 $\pm$ 9.6 (107)	inactive	inactive
2-Aminobenzothiazole		5	inactive	inactive	inactive









2-Chloro-p-phenylenediamine SO <sub>4</sub>		4	17.1 ± 4.1 (72)	inactive	26.5 ± 6.0 (83)
3,5-Dichloroaniline		4	inactive	inactive	inactive
3-Dimethylaminophenol		7	inactive	inactive	inactive
4-Chloro-o-phenylenediamine		4	inactive	inactive	27.2 ± 3.7 (111.2)
8-Hydroxyquinoline		1	16.1 ± 5.1 (53)	inactive	10.1 ± 3.9 (200)
Acetochlor		8	4.7 ± 1.6 (86)	inactive	21.9 ± 5.3 (78)
Alachlor		8	5.9 ± 1.7 (106)	inactive	19.9 ± 7.1 (127)
Benzo(b)fluoranthene		9	5.9 ± 3.0 (136)	23.4 ± 1.6 (134)	1.3 ± 1.0 (19)
Benzo(k)fluoranthene		9	1.6 ± 0.7 (114)	18.4 ± 5.1 (160)	4.9 ± 2.2 (103)
Bisphenol A		10	12.5 ± 5.6 (48)	inactive	inactive



Cadmium II chloride		11	inactive	inactive	$1.1 \pm 0.1$ (446)
Chlorambucil		8	inactive	inactive	inactive
Chlorendic acid		12	inactive	inactive	inactive
Curcumin		13	$3.2 \pm 3.2$ (21)	inactive	$10.8 \pm 0.7$ (165)
D & C Yellow II		14	$0.7 \pm 0.1$ (88)	$3.2 \pm 0.4$ (48)	$1.2 \pm 0.7$ (185)
Dazomet		15	$20.1 \pm 6.6$ (55)	inactive	$26.6 \pm 2.2$ (22)
Dieldrin		12	$15.5 \pm 11.8$ (40)	inactive	$14.2 \pm 15.0$ (27)
Flavone		16	$2.4 \pm 0.6$ (80)	inactive	$7.6 \pm 0.5$ (47)
Fluoranthene		9	inactive	inactive	inactive


Guggulsterones E		17	$5.0 \pm 3.1$ (106)	inactive	$15.4 \pm 2.6$ (115)
Indium trichloride		11	$14.8 \pm 4.9$ (92)	inactive	$25.0 \pm 0$ (312)
Iodochlorohydroxyquinoline		1	$17.2 \pm 6.0$ (41)	$19.2 \pm 4.6$ (21)	$10.0 \pm 1.2$ (147)
Lithocholic acid		18	$17.7 \pm 5.7$ (65)	inactive	$21.9 \pm 8.2$ (61)
Melphalan		8	inactive	inactive	inactive
n-(1,3-Dimethylbutyl)-n'-phenyl-p-phenylenediamine		19	$17.3 \pm 5.0$ (89)	inactive	inactive
N,N-Diethyl-p-phenylenediamine		19	$18.7 \pm 7.6$ (60)	inactive	inactive

N,N-Dimethyl-p-nitrosoaniline		7	$9.9 \pm 3.4$ (82)	inactive	$29.2 \pm 2.0$ (626)
N,N-Dimethyl-p-phenylenediamine		7	$9.6 \pm 0.6$ (80)	inactive	$11.8 \pm 4.4$ (24)
N-Isopropyl-N'-phenyl-p-phenylenediamine		19	$13.1 \pm 8.9$ (71)	inactive	inactive
Nitrogen mustard HCl		20	$10.4 \pm 3.6$ (46)	inactive	$10.4 \pm 0.7$ (789)
N-Methyl-p-aminophenol sulfate*		7	$13.6 \pm 3.2$ (37)	inactive	$24.6 \pm 9.2$ (202)
o-Aminophenol		21	$6.8 \pm 4.1$ (95)	inactive	$26.2 \pm 3.3$ (234)
o-Phenylenediamine		22	$7.2 \pm 4.1$ (72)	inactive	$27.3 \pm 4.7$ (151)
p,p'-DDE		23	inactive	inactive	inactive


Phenylthiourea		19	inactive	inactive	inactive
p-Nitrosodiphenylamine		24	$9.7 \pm 4.1$ (31)	inactive	$21.7 \pm 3.7$ (71)
Quinoline		1	inactive	inactive	inactive
Rhothane (TDE)		23	$16.4 \pm 7.3$ (43)	inactive	$13.5 \pm 3.3$ (32)
Sodium Cholate		18	inactive	inactive	inactive
Teroxironum		25	$5.9 \pm 1.9$ (119)	inactive	$27.1 \pm 1.8$ (1541)
Tetraethylene glycol diacrylate		26	$9.5 \pm 4.8$ (53)	inactive	$29.2 \pm 2.0$ (288)
Tetramethylthiuram disulfide		15	$17.2 \pm 4.9$ (35)	inactive	$30.6 \pm 5.2$ (265)

Abbreviations: DDE=Dichlorodiphenyl dichloroethylene; TDE=Tetrachlorodiphenylethane

Each value of potency ( $EC_{50}$ ,  $\mu M$ ) and efficacy (activation of ARE reporter as a % of positive control) from ARE cell-based assays is the mean  $\pm$  SD of replicates from one (ARE-*luc*) to two (ARE-*bla*) experiments.



**Supplemental Material, Figure S1:** Heat map of all follow-up compounds tested in ARE-*bla*, ARE-*bla*-mut, and ARE-*luc* assays. Activity shown was based on log10-transformed compound EC<sub>50</sub> values across all assays. Each row represents a compound and each column represents a follow-up assay. The heat maps were clustered by pattern and colored based on compound activity, where activity in the assay is colored red, less conclusive activators are colored a lighter shade of red, and inactive compounds are white.



**Supplemental Material, Figure S2:** A flowchart of identification of ARE inducers in multiple assay formats using qHTS. One hundred and forty-one compounds were commonly active between the ARE-*bla* and ARE-*luc* assays in the primary screen and 34 of those compounds were high quality actives with curve classes 1.1, 2.1, 2.1, and 2.2. These compounds, along with compounds with various activity profiles across different SAR clusters were chosen for follow-up testing, resulting in 63 compounds. Quality control analysis confirmed the identity of 50/63 compounds, hence these were re-tested in the ARE-*bla*, ARE-*luc*, ARE-*bla*-mut and luciferase inhibition (latter 2 assays not shown in the diagram) assays. Forty-seven and 45 compounds confirmed activity in the ARE-*bla* and ARE-*luc* assays, respectively.

## References

- Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al. 2006. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. *Proc Natl Acad Sci USA* 103(31):11473–11478.
- Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, et al. 2011. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. *Environmental health perspectives* 119(8):1142-1148.
- Simmons SO, Fan CY, Yeoman K, Wakefield J, Ramabhadran R. 2011. NRF2 Oxidative Stress Induced by Heavy Metals is Cell Type Dependent. *Current chemical genomics* 5:1-12.
- Xia M, Huang R, Witt KL, Southall N, Foster J, Cho MH, et al. 2008. Compound cytotoxicity profiling using quantitative high-throughput screening. *Environmental health perspectives* 116(3):284-291.